RXRγ Antagonist
-
F44-A13
0 ImagesCat. No.: HY-163436CAS No.: 1338190-14-9F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
-
RARγ antagonist 1
0 ImagesCat. No.: HY-186156CAS No.: 859498-19-4RARγ antagonist 1 (Compound in claim 4, P20) is a RARγ antagonist. RARγ antagonist 1 can be used for the researches of inflammation and immunology.
-
AGN 193109 sodium
0 ImagesCat. No.: HY-U00449ACAS No.: 2319838-82-7AGN 193109 sodium is the sodium salt form of AGN 193109 (HY-U00449). AGN 193109 sodium is the pan antagonist for retinoic acid receptor (RAR), with Kd of 2, 2 and 3 nM, for RARα, RARβ and RARγ, respectively. AGN 193109 sodium reverses TTNPB-induced morphology changes and all-trans retinoic acid (tRA)/9-cis RA/13-cis RA-induced proliferation suppression in ECE16-1 cell. AGN 193109 sodium is the antidote for retinoic acidosis, that ameliorates the skin and mucosal toxicity.
